
HeartBeam (BEAT) Stock Forecast & Price Target
HeartBeam (BEAT) Analyst Ratings
Bulls say
HeartBeam is showing promising results with its expanded commercial launch of hand-held ECG, initiation of a pilot study for 12-lead extended wear patch capable of detecting ischemia, and ahead of schedule patient enrollment for a pilot study on heart attack detection. In addition, the company's strategic collaboration with Mount Sinai and disciplined cost management are positive indicators for future success. However, there are risks involved such as failure in clinical trials, competition, dilution and going concern that should be taken into consideration.
Bears say
HeartBeam is seeing initial success with the commercial launch of their ECG solutions through partnerships with ClearCardio and Atelier Health, targeting a potential ARR opportunity of $75M-$150M in the direct pay segment. Additionally, their innovative 12-lead extended wear patch technology has generated interest in the industry, potentially disrupting the $2B MCT segment with the ability to detect ischemia and utilizing existing reimbursement codes. The company's recent pilot study and meetings with larger industry players at major conferences have further bolstered interest in strategic partnerships for bringing the patch to market.
This aggregate rating is based on analysts' research of HeartBeam and is not a guaranteed prediction by Public.com or investment advice.
HeartBeam (BEAT) Analyst Forecast & Price Prediction
Start investing in HeartBeam (BEAT)
Order type
Buy in
Order amount
Est. shares
0 shares